[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer+1 More
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone - Drug
Eligibility
Any Age
Male
What conditions do you have?
Select

Study Summary

This trial will use PET scans with a radiotracer to see if it can more accurately find where prostate cancer has spread in the body.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 years

2 years
To correlate the accumulation of 18FDHT to 18FDG.
To study changes in 18FDHT accumulation over time in patients treated with: Castration and other hormones, Chemotherapy, Agents directed toward the androgen receptor
relationship between FDHT uptake and tissue analyses
relationship between FDHT uptake and tumor diffusivity
Week 12
To study the accumulation and biodistribution of FDHT in patients with progressive prostate cancer. The accumulation and location of FDHT activity will be assessed on a site by site basis and correlated with radionuclide bone scan, CT and MRI.
Week 12
The kinetics, metabolism, and biodistribution will be assessed.

Trial Safety

Trial Design

1 Treatment Group

1
1 of 1
Experimental Treatment

300 Total Participants · 1 Treatment Group

Primary Treatment: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone · No Placebo Group · N/A

1
Drug
Experimental Group · 1 Intervention: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,051 Total Patients Enrolled
127 Trials studying Prostate Cancer
65,126 Patients Enrolled for Prostate Cancer
Michael Morris, M.D., Ph.D.Principal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age Any Age · Male Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have given informed consent to participate in this study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.